SCHEMBL236458

SCHEMBL236458

Clc1ccc2c(c1)Nc1ccccc1S2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 12/20 1.00
BCHE P06276 3/20 1.00
ACHE P22303 3/20 1.00
MAPT P10636 6/20 0.65
GAA P10253 5/20 0.65
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
SNCA P37840 3/20 0.65
ALOX15 P16050 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
CYP1A2 P05177 1/20 0.65
POLB P06746 1/20 0.65
CYP3A4 P08684 1/20 0.65
ADORA3 P0DMS8 1/20 0.65
ALOX12 P18054 1/20 0.65
MAOA P21397 1/20 0.65
CNR1 P21554 1/20 0.65
PTGS1 P23219 1/20 0.65
SLC6A2 P23975 1/20 0.65
HTR2C P28335 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29384266 1.00 NOX1 (1.00) NOX1BCHEACHEMAPTGAA
SCHEMBL28679021 0.98 NOX1 (0.96) NOX1BCHEACHEMAPTGAA
SCHEMBL28232162 0.98 NOX1 (0.96) NOX1BCHEACHEMAPTGAA
SCHEMBL1509893 0.92 NOX1 (0.84) NOX1BCHEACHEMAPTGAA
SCHEMBL28117966 0.90 NOX1 (0.81) NOX1BCHEACHEMAPTGAA
SCHEMBL4670416 0.89 NOX1 (0.79) NOX1BCHEACHEMAPTGAA
Urea SCHEMBL27590816 0.89 NOX1 (0.79) NOX1BCHEACHEMAPTGAA
SCHEMBL30769670 0.89 NOX1 (0.79) NOX1BCHEACHEMAPTGAA
SCHEMBL239261 0.89 NOX1 (0.79) NOX1BCHEACHEMAPTGAA
SCHEMBL28117917 0.86 NOX1 (0.76) NOX1BCHEACHEMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255879-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-08-14 US claimed
CN-119751437-A Synthesis method of Se-deuterated methyl-thioridazine compound 浙江工业大学 2025-04-04 CN claimed
CN-118930860-A Preparation method of polymer containing sulfonyl and sulfonic acid 太原理工大学 2024-11-12 CN claimed
US-20230330095-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2023-10-19 US claimed
EP-4260861-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR Seoul National University R & DB Foundation (KR) 2023-10-18 EP claimed
CN-112954836-B Electrothermal film based on graphene electrothermal and preparation method thereof 张标 2023-09-29 CN claimed
CN-113109474-B Method for detecting sedative drug metabolism residues in animal tissues 吉林省农业科学院 2023-08-01 CN claimed
CN-113512033-B Phenoxazine and phenothiazine covalent triazine framework material, and preparation method and application thereof 南京工业大学 2023-06-16 CN claimed
CN-114574147-A Solvent-free polyurethane adhesive 陈文娟 2022-06-03 CN claimed
CN-113429366-B Preparation method of chlorpromazine hydrochloride 常州康普药业有限公司 2022-03-08 CN claimed
WO-2008027345-A2 COMBINED γ-SECRETASE INHIBITOR AND PHENOTHIAZINE DERIVATIVE TREATMENT OF NEURODEGENERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-03-06 WO claimed
CN-1255390-C Preparation of 2-cyanophenthiazine UNIV SHANXI (CN) 2006-05-10 CN claimed
US-20050209173-A1 Neurodegenerative protein aggregation inhibition methods and compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-09-22 US claimed
CN-1583732-A Preparation of 2-cyanophenthiazine UNIV SHANXI (CN) 2005-02-23 CN claimed
WO-2005011610-A2 NEURODEGENERATIVE PROTEIN AGGREGATION INHIBITION METHODS AND COMPOUNDS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2005-02-10 WO claimed
US-5391465-A Using phenothiazine or phenoxazine compounds ROHM AND HAAS COMPANY (US) 1995-02-21 US claimed
CN-1048931-A In the acid hardening photoresist of high resolution, adopt the method for the Photoactive compounds of selecting by near ultraviolet radiation ROHM & HAAS (US) 1991-01-30 CN claimed
EP-0404499-A2 Photosensitive compositions comprising selected photoactive materials and their use in producing high resolution, photoresist images with near ultraviolet radiation ROHM AND HAAS COMPANY (US) 1990-12-27 EP claimed
US-4407800-A TRYPANOCIDES UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1983-10-04 US claimed
US-4249003-A Process for polycyclic amines AKTIEBOLAGET LEO (SE) 1981-02-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330095-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR NUP205, NUP50, NUP188 NOX1 3666/4885BCHE 3903/4885ACHE 4269/4885
US-20250255879-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR NUP205, NUP188, NUP50 NOX1 3568/4885BCHE 4097/4885ACHE 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.